STOCK TITAN
  1. Home
  2. News
  3. APLS

Apellis Pharmaceuticals Inc - APLS STOCK NEWS

Welcome to our dedicated news page for Apellis Pharmaceuticals (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Apellis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Apellis Pharmaceuticals's position in the market.

News
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Rhea-AI Summary
Apellis Pharmaceuticals to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences
-
News
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
Rhea-AI Summary
Apellis Pharmaceuticals announces corporate restructuring to drive growth of SYFOVRE and EMPAVELI, with anticipated cost savings of up to $300 million through 2024. SYFOVRE generates $85.7 million in U.S. net product revenues in H1 2023. Workforce reduction of approximately 25% and elimination of planned external expenses. Decision on regulatory approval for SYFOVRE in the EU expected in early 2024. Top-line data from Phase 3 VALIANT study for systemic pegcetacoplan expected in 2024. Prioritizing research initiatives in retina and CNS diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
none
-
News
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
Rhea-AI Summary
Apellis Pharmaceuticals provides update on injection kits and events of retinal vasculitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.17%
Tags
none
News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Apellis Pharmaceuticals approves grant of equity awards to 13 new employees, with each employee receiving 23,015 restricted stock units (RSUs). RSUs will vest annually based on continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Apellis Pharmaceuticals announced its second quarter 2023 financial results and business highlights. They reported total U.S. net product revenues of $89.6 million, including $67.3 million for SYFOVRE and $22.3 million for EMPAVELI. SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30. Investigation on recently reported rare safety events with SYFOVRE found no indication of drug product or manufacturing issues. Cash and cash equivalents were $616.3 million as of June 30, 2023, with expected cash runway into Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.58%
Tags
earnings
-
News
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
Rhea-AI Summary
Apellis Pharmaceuticals announces positive data from the GALE extension study of SYFOVRE in the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham. Safety profile of SYFOVRE was consistent with previous clinical data. Data presented at the ASRS Annual Scientific Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
Rhea-AI Summary
Apellis Pharmaceuticals provides an update on rare events of retinal vasculitis associated with SYFOVRE, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Seven total events of retinal vasculitis have been confirmed since launch, with no indication of drug product or manufacturing issues contributing to these events. No events were reported in clinical trials. Apellis continues to prioritize patient safety and collaborate with the retina community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) to discuss second quarter 2023 financial results in conference call and webcast. Investors can access live call and webcast through company website. Replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
conferences earnings
-
News
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
Stock APLS logo
Apellis Pharmaceuticals Inc

Nasdaq:APLS

APLS Rankings

#1112 Ranked by Market Cap
#3412 Ranked by Stock Gains
N/A Ranked by Dividends

APLS Stock Data

6.25B
81.04M
13.24%
95.98%
8.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Waltham

About APLS

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.